Prospects for new drugs for chronic obstructive pulmonary disease
Authors:
- Peter J BarnesPeter J Barnes
- Trevor T HanselTHTrevor T Hansel
- 1 September 2004
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 364 (9438) , 985-996
Abstract
No abstract availableKeywords
This publication has 113 references indexed in Scilit:
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmaticsThe FASEB Journal, 2003
- Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbationsThorax, 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPDEuropean Respiratory Journal, 2002
- Lung epithelial stem cellsThe Journal of Pathology, 2002
- Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophagesThe FASEB Journal, 2001
- p38 MAP kinase and MKK‐1 co‐operate in the generation of GM‐CSF from LPS‐stimulated human monocytes by an NF‐κB‐independent mechanismBritish Journal of Pharmacology, 2000
- Proteinase-activated receptor-2–mediated matrix metalloproteinase-9 release from airway epithelial cellsJournal of Allergy and Clinical Immunology, 2000
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000